54
Participants
Start Date
June 30, 2006
Primary Completion Date
March 31, 2008
Study Completion Date
July 31, 2008
aprepitant
Aprepitant 125 mg by mouth (PO) on day 1 and 80 mg PO on days 2 and 3 of each chemotherapy cycle
dexamethasone
Dexamethasone 12 mg PO on 1st day of study drug and 8 mg PO on days 2-4
fluorouracil
as per institutional standard of care
irinotecan hydrochloride
as per institutional standard of care
leucovorin calcium
as per institutional standard of care
oxaliplatin
as per institutional standard of care
palonosetron hydrochloride
Palonosetron 0.25 mg IV push on day 1 only.
quality-of-life assessment
baseline
St. Josephs/Cander Hospital, Savannah
Ingalls Memorial Hospital, Harvey
Kansas City Cancer Center, Kansas City
Texas A & M university / Scott and White Clinic, Temple
Kaiser Permanente, Hilo
OHSU Knight Cancer Institute, Portland
National Cancer Institute (NCI)
NIH
OHSU Knight Cancer Institute
OTHER